New use for an old drug: Metformin and atrial fibrillation

Manlio Vinciguerra, Ivan Olier, Sandra Ortega-Martorell, Gregory Y H Lip, Manlio Vinciguerra, Ivan Olier, Sandra Ortega-Martorell, Gregory Y H Lip

Abstract

Lal and colleagues1 reported an integrative approach-combining transcriptomics, iPSCs, and epidemiological evidence-to identify and repurpose metformin, a main first-line medication for the treatment of type 2 diabetes, as an effective risk reducer for atrial fibrillation.

Conflict of interest statement

Declaration of interests The authors declare no competing interests.

Copyright © 2022 The Author(s). Published by Elsevier Inc. All rights reserved.

References

    1. Lal J.C., Mao C., Zhou Y., Gore-Panter S.R., Rennison J.H., Lovano B.S., Castel L., Shin J., Gillinov A.M., Smith J.D., et al. Transcriptomics-based network medicine approach identifies metformin as a repurposable drug for atrial fibrillation. Cell Rep. Med. 2022;3:100749. doi: 10.1016/j.xcrm.2022.100749.
    1. Chao T.F., Joung B., Takahashi Y., Lim T.W., Choi E.K., Chan Y.H., Guo Y., Sriratanasathavorn C., Oh S., Okumura K., Lip G.Y.H. 2021 focused update consensus guidelines of the Asia Pacific heart rhythm society on stroke prevention in atrial fibrillation: Executive summary. Thromb. Haemost. 2022;122:020–047. doi: 10.1055/S-0041-1739411.
    1. Han N., Hwang W., Tzelepis K., Schmerer P., Yankova E., MacMahon M., Lei W., M Katritsis N., Liu A., Felgenhauer U., Schuldt A., Harris R., Chapman K., McCaughan F., Weber F., Kouzarides T. Identification of SARS-CoV-2–induced pathways reveals drug repurposing strategies. Sci. Adv. 2021;7:eabh3032. doi: 10.1126/sciadv.abh3032.
    1. Dönertaş H.M., Fuentealba Valenzuela M., Partridge L., Thornton J.M. Gene expression-based drug repurposing to target aging. Aging Cell. 2018;17 doi: 10.1111/ACEL.12819.
    1. Barzilai N., Crandall J.P., Kritchevsky S.B., Espeland M.A. Metformin as a tool to target aging. Cell Metab. 2016;23:1060–1065. doi: 10.1016/J.CMET.2016.05.011.
    1. Zhou Y., Wang F., Tang J., Nussinov R., Cheng F. Artificial intelligence in COVID-19 drug repurposing. Lancet Digit. Health. 2020;2:e667–e676. doi: 10.1016/S2589-7500(20)30192-8.
    1. Nguyen T., Le H., Quinn T.P., Nguyen T., Le T.D., Venkatesh S. GraphDTA: predicting drug–target binding affinity with graph neural networks. Bioinformatics. 2021;37:1140–1147. doi: 10.1093/bioinformatics/btaa921.
    1. Olier I., Orhobor O.I., Dash T., Davis A.M., Soldatova L.N., Vanschoren J., King R.D. Transformational machine learning: learning how to learn from many related scientific problems. Proc. Natl. Acad. Sci. USA. 2021;118 doi: 10.1073/pnas.2108013118.
    1. Romiti G.F., Pastori D., Rivera-Caravaca J.M., Ding W.Y., Gue Y.X., Menichelli D., Gumprecht J., Kozieł M., Yang P.S., Guo Y., Lip G.Y., Proietti M. Adherence to the “atrial fibrillation better care” pathway in patients with atrial fibrillation: Impact on clinical outcomes-A systematic review and meta-analysis of 285,000 patients. Thromb. Haemost. 2022;122:406–414. doi: 10.1055/A-1515-9630.
    1. Romiti G.F., Proietti M., Bonini N., Ding W.Y., Boriani G., Huisman M.v., et al. GLORIA-AF Investigators Clinical complexity domains, anticoagulation, and outcomes in patients with atrial fibrillation: a report from the GLORIA-AF Registry Phase II and III. Thromb. Haemost. 2022;122:2030–2041. doi: 10.1055/S-0042-1756355.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir